{"preliminary_commentary":{"by_channel":{"x_thread":11},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04523272\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["benmelstobart","anlotinib"]],"indication":"first-line advanced renal cell carcinoma","name":"ETER100","nct_id":"NCT04523272","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=eter100-nct04523272. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).","label":"TQB2450 + Anlotinib","type":"EXPERIMENTAL"},{"description":"Sunitinib malate capsule 50mg administered orally, once daily in 28-day cycle(14 days on treatment from Day 1-14, 14 days off treatment from day 15-28).","label":"Sunitinib Malate Capsules","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2025-12","type":"ESTIMATED"},"conditions":["Advanced Renal Cancer"],"enrollment":{"count":528,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"TQB2450","otherNames":[],"type":"DRUG"},{"name":"Anlotinib","otherNames":[],"type":"DRUG"},{"name":"Sunitinib","otherNames":[],"type":"DRUG"}],"last_update":"2024-10-15","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","official_title":"A Randomized, Positive Parallel Controlled, Multicenter Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer","overall_status":"UNKNOWN","phases":["PHASE3"],"primary_completion_date":{"date":"2025-06","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival (PFS) evaluated by Independent Review Committee(IRC)","timeFrame":"up to 60 weeks"}],"references":[{"citation":"Li J, Tian H, Xu H, Yan X, Tang B, Li S, Zhou L, Wu X, Chi Z, Cui C, Si L, Guo J, Sheng X. Evaluation and analysis of renal injury in patients with advanced renal cell carcinoma receiving first-line benmelstobart plus anlotinib: results from the ETER100 study. BMC Med. 2026 Jul 1. doi: 10.1186/s12916-026-05026-0. Online ahead of print.","pmid":"42387482","type":"DERIVED"},{"citation":"Zhou A, Shen P, Li J, Qu W, Wang Z, Ren X, Li Y, Jiang S, Li G, Zeng Y, Qin W, Wu J, Chen P, Zhou F, Guo H, Ji Z, Wang Y, He Z, Wu J, Shi B, Liu L, Yao X, Ma L, Liu Z, Gou X, Fu B, Wang S, Jiang K, Chong T, Tu X, Zhang X, Yu D, Rexiati M, Xue X, Fei J, Wan J, Jia L, He Y, Cui T, Yang AQ, Guo J, Sheng X. First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Sep;26(9):1145-1157. doi: 10.1016/S1470-2045(25)00343-2.","pmid":"40907513","type":"DERIVED"}],"start_date":{"date":"2020-08-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer","url":"https://clinicaltrials.gov/study/NCT04523272"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/eter100-nct04523272"}